aTyr Pharma offers a potentially FDA-aligned clinical resurrection story, but investors must survive dilution, delisting risk, and another pivotal trial before the upside can matter.
Overview
aTyr Pharma is a distressed clinical-stage biotech attempting a high-risk turnaround after EFZO-FIT missed its Phase 3 primary endpoint, triggering an 80% share-price collapse. FDA alignment on a new C-006 Phase 3 trial in restrictive pulmonary sarcoidosis creates a credible second chance, supported by encouraging subgroup FVC data. However, the company’s $68.3 million cash balance is likely insufficient for a 372-patient global trial, making dilution, reverse split risk, and Nasdaq compliance central investor concerns.